[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@PeptidreamInc](/creator/twitter/PeptidreamInc)
"Today we released our Q2 earnings report which includes two significant capital investments to support our long-term growth and expansion strategy"  
[X Link](https://x.com/PeptidreamInc/status/1953711133107315108) [@PeptidreamInc](/creator/x/PeptidreamInc) 2025-08-08T06:53Z XX followers, XXX engagements


"📹We are excited to announce that we will be presenting the Group's proprietary program PD-32766 at #EANM25 this weekend PD-32766 is a peptide-based theranostic agent targeting CA9 currently under development for ccRCC. #radiopharmaceutical #theranostics #RCC #CA9 #CAIX"  
[X Link](https://x.com/PeptidreamInc/status/1973572206572740679) [@PeptidreamInc](/creator/x/PeptidreamInc) 2025-10-02T02:14Z XX followers, XXX engagements


"Our CFO Dr. Kaneshiro spoke at Panel Session X of the NIKKEI Drug Discovery Ecosystem Summit. He shared insights into our growth strategy and global pharma partnerships. 📺 Watch the full session here"  
[X Link](https://x.com/PeptidreamInc/status/1942114675157852374) [@PeptidreamInc](/creator/x/PeptidreamInc) 2025-07-07T06:53Z XX followers, XXX engagements


"We started the development of 64Cu-PSMA-I&T for advanced prostate cancer as part of a registrational trial in Japan. In parallel we are also planning to start a clinical trial for its therapeutic pair 117Lu-PSMA-I&T. Press"  
[X Link](https://x.com/PeptidreamInc/status/1980128743059529796) [@PeptidreamInc](/creator/x/PeptidreamInc) 2025-10-20T04:27Z XX followers, XX engagements